Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: A phase 1 study

Journal of Infectious Diseases

Volumn 190, Issue 11, 2004, Pages 1957-1961

  Gewurz, Benjamin E ^a   Jacobs, Mark ^c   Proper, Jo Ann ^a   Dahl, Thomas A ^b   Fujiwara, Tamio ^d   Dezube, Bruce J ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Lexigen Pharmaceuticals Corp   (United States)

^c Saint Francis Memorial Hospital   (United States)

^d SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAPRAVIRINE; INDINAVIR; KETOCONAZOLE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG POTENCY; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SLEEP DISORDER; T LYMPHOCYTE; TASTE DISORDER; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ADMINISTRATION, ORAL; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIARRHEA; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMIDAZOLES; MALE; NAUSEA; REVERSE TRANSCRIPTASE INHIBITORS; SULFUR COMPOUNDS; VIRAL LOAD;

EID: 9444225975     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/425581     Document Type: Article

References (15)

1. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-94.
2. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 1995; 2:303-8.
3. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995; 267:988-93.
4. Zhou Z, Madrid M, Madura JD. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase. Proteins 2002; 49:529-42.
5. Deeks SG. International perspectives on antiretroviral resistance: non-nucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 2001; 26(Suppl 1):S25-33.
6. Clotet B. Efavirenz: resistance and cross-resistance. Int J Clin Pract Suppl 1999; 103:21-5.
7. Haubrich RH, Kemper CA, Hellmann NS, et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS 2002; 16:F33-40.
8. Fujiwara T, Sato A, El-Farrash M, et al. S-1153 inhibits replication of known drug-resistant strains of HIV-1. Antimicrob Agents Chemother 1998; 42:1340-45.
9. Ren J, Nichols C, Bird LE, et al. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J Biol Chem 2000; 275:14316-20.
10. 3 (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis 1998; 177:617-24.
11. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infections. N Engl J Med 1998; 338:853-60.
12. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-30.
13. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-9.
14. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA panel. JAMA 2002; 288:222-35.
15. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2003; 37:113-28.